Publication:
A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines

dc.contributor.authorDorota Smolareken_US
dc.contributor.authorClaude Hattaben_US
dc.contributor.authorGholamreza Hassanzadeh-Ghassabehen_US
dc.contributor.authorSylvie Cocheten_US
dc.contributor.authorCarlos Gutiérrezen_US
dc.contributor.authorAlexandre G. De Brevernen_US
dc.contributor.authorRachanee Udomsangpetchen_US
dc.contributor.authorJulien Picoten_US
dc.contributor.authorMagdalena Grodeckaen_US
dc.contributor.authorKazimiera Wasniowskaen_US
dc.contributor.authorSerge Muyldermansen_US
dc.contributor.authorYves Colinen_US
dc.contributor.authorCaroline Le Van Kimen_US
dc.contributor.authorMarcin Czerwinskien_US
dc.contributor.authorOlivier Bertranden_US
dc.contributor.otherInsermen_US
dc.contributor.otherLudwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciencesen_US
dc.contributor.otherInstitut National de la Transfusion Sanguineen_US
dc.contributor.otherUniversite Paris 7- Denis Dideroten_US
dc.contributor.otherVrije Universiteit Brusselen_US
dc.contributor.otherFlanders Interuniversity Institute for Biotechnologyen_US
dc.contributor.otherUniversidad de Las Palmas de Gran Canariaen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-09-24T08:42:50Z
dc.date.available2018-09-24T08:42:50Z
dc.date.issued2010-10-01en_US
dc.description.abstractFy blood group antigens are carried by the Duffy antigen receptor for chemokines (DARC), a red cells receptor for Plasmodium vivax broadly implicated in human health and diseases. Recombinant VHHs, or nanobodies, the smallest intact antigen binding fragment derivative from the heavy chain-only antibodies present in camelids, were prepared from a dromedary immunized against DARC N-terminal extracellular domain and selected for DARC binding. A described VHH, CA52, does recognize native DARC on cells. It inhibits P. vivax invasion of erythrocytes and displaces interleukin-8 bound to DARC. The targeted epitope overlaps the well-defined DARC Fy6 epitope. KDof CA52-DARC equilibrium is sub-nanomolar, hence ideal to develop diagnostic or therapeutic compounds. Immunocapture by immobilized CA52 yielded highly purified DARC from engineered K562 cells. This first report on a VHH with specificity for a red blood cell protein exemplifies VHHs' potentialities to target, to purify, and to modulate the function of cellular markers. © 2010 Springer Basel AG.en_US
dc.identifier.citationCellular and Molecular Life Sciences. Vol.67, No.19 (2010), 3371-3387en_US
dc.identifier.doi10.1007/s00018-010-0387-6en_US
dc.identifier.issn14209071en_US
dc.identifier.issn1420682Xen_US
dc.identifier.other2-s2.0-77956759905en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/28636
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956759905&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectNeuroscienceen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleA recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokinesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956759905&origin=inwarden_US

Files

Collections